Humoral responses to SARS-CoV-2 by healthy and sick dogs during the COVID-19 pandemic in Spain by Perisé-Barrios, A.J. et al.
Perisé‑Barrios et al. Vet Res           (2021) 52:22  
https://doi.org/10.1186/s13567‑021‑00897‑y
RESEARCH ARTICLE
Humoral responses to SARS‑CoV‑2 
by healthy and sick dogs during the COVID‑19 
pandemic in Spain
Ana Judith Perisé‑Barrios1* , Beatriz Davinia Tomeo‑Martín1 , Pablo Gómez‑Ochoa2, Pablo Delgado‑Bonet1 
, Pedro Plaza3, Paula Palau‑Concejo1 , Jorge González4, Gustavo Ortiz‑Díez5, Antonio Meléndez‑Lazo6, 
Michaela Gentil6, Javier García‑Castro7  and Alicia Barbero‑Fernández5* 
Abstract 
COVID‑19 is a zoonotic disease caused by SARS‑CoV‑2. Infections of animals with SARS‑CoV‑2 have recently been 
reported, and an increase of severe lung pathologies in domestic dogs has also been detected by veterinarians in 
Spain. Therefore, further descriptions of the pathological processes in those animals that show symptoms similar to 
those described in humans affected by COVID‑19 would be highly valuable. The potential for companion animals 
to contribute to the continued transmission and community spread of this known human‑to‑human disease is an 
urgent issue to be considered. Forty animals with pulmonary pathologies were studied by chest X‑ray, ultrasound 
analysis, and computed tomography. Nasopharyngeal and rectal swabs were analyzed to detect canine pathogens, 
including SARS‑CoV‑2. An additional twenty healthy dogs living in SARS‑CoV‑2‑positive households were included. 
Immunoglobulin detection by several immunoassays was performed. Our findings show that sick dogs presented 
severe alveolar or interstitial patterns with pulmonary opacity, parenchymal abnormalities, and bilateral lesions. The 
forty sick dogs were negative for SARS‑CoV‑2 but Mycoplasma spp. was detected in 26 of 33 dogs. Five healthy and 
one pathological dog presented IgG against SARS‑CoV‑2. Here we report that despite detecting dogs with α‑SARS‑
CoV‑2 IgG, we never obtained a positive RT‑qPCR for SARS‑SoV‑2, not even in dogs with severe pulmonary disease; 
suggesting that even in the case of canine infection, transmission would be unlikely. Moreover, dogs living in COVID‑
19‑positive households could have been more highly exposed to infection with SARS‑CoV‑2.
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Introduction
The year 2020 has seen an international health emer-
gency generated by the emerging zoonotic coronavirus 
SARS-CoV-2, which began its expansion in the end of the 
2019 in Wuhan (China) and caused a pandemic within 
a few months [1, 2]. SARS-CoV-2 infection can lead to 
COVID-19, a pathology with various clinical manifesta-
tions, and in its severest form is mainly associated with 
lung injury and pathology similar to macrophage acti-
vation syndrome, such as hyperinflammation and lung 
damage by an uncontrolled activation and proliferation 
of T lymphocytes and macrophages [3, 4].
Four genera of coronaviruses have been described: 
Alphacoronavirus, Betacoronavirus, Gammacorona-
virus and Deltacoronavirus (α-CoV, β-CoV, γ-CoV and 
δ-CoV) according to their genetic structure. α-CoV and 
β-CoV infect mammals, and in addition to humans, 
have been also described in dogs and cats. Mostly, they 
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are responsible for respiratory infections in humans and 
gastroenteritis in animals. In dogs, canine enteric coro-
navirus (CCoV), an α-CoV, causes an enteritis of variable 
severity that is rarely fatal but leads to the development 
of immunity. However, some recovered dogs become 
carriers with the ability to infect other dogs. However, 
canine respiratory coronavirus (CRCoV), which belongs 
to the β-CoV (like SARS-CoV-2), causes respiratory 
symptoms in dogs, with generally mild clinical signs [5] 
and occasionally as a coinfection with other respiratory 
pathogens. Recently, the first cases of asymptomatic dogs 
infected with SARS-CoV-2 have been described [6].
Due to the zoonotic origin of SARS-CoV-2 and the 
described transmission between species, a hypothesis of 
the transmission and spread among animals of different 
species has become more plausible [7]. Cases of infected 
cats, dogs, tigers, lions, minks and ferrets have been 
reported during SARS-CoV-2 outbreaks, all of which had 
had close contact with infected people [6, 8]. Some data 
suggest that transmission from minks to humans, cats 
and dogs has occurred on farms.
The World Organization for Animal Health (OIE) 
stated that some animals can become infected by being 
in permanent contact with infected people, although 
they note that there is no evidence pointing to a role 
of infected pets in the spread of SARS-CoV-2. To 
date, no cases of transmission from domestic animals 
to humans have been described [9]. Some researchers 
have reported that dogs whose owners were positive 
for SARS-CoV-2 showed negative serological results to 
SARS-CoV-2, postulating that pets are not virus car-
riers [10]. By contrast, there have been some cases of 
companion dogs reported to be positive by quantita-
tive reverse transcription PCR (RT-qPCR)detection [6] 
and others that have developed neutralizing antibod-
ies against SARS-CoV-2 [11]. RT-qPCR-positive dogs 
have been detected worldwide (Hong Kong, Denmark 
and USA, but none in Spain), all of them in close con-
tact with SARS-CoV-2 positive humans [9]. Currently, 
28 positive dogs to SARS-CoV-2 have been reported 
by RT-qPCR around the world. Less than half of them 
were asymptomatic [6, 12]. One presented mild respira-
tory illness, and only one presented also neutralizing 
antibodies accompanied with hemolytic anemia [13]. 
On the other hand, two PCR-negative dogs have devel-
oped neutralizing antibodies. One was asymptomatic 
and the other had breathing problems, but it is not clear 
if this was related to the infection [13]. Further, molec-
ular testing of 3500 companion dogs, cats and horses 
were done by IDEXX Company in USA and Korea and 
no positive cases were found [14]. No positive cases 
have been reported in dogs exposed to SARS-CoV-2 in 
France [15]. Another recent study in Italy carried out 
with pets has shown that none of the 817 animals stud-
ied were positive for SARS-CoV-2 by RT-qPCR test but 
13 dogs and 6 cats had neutralizing antibodies [11].
In this report, we show that during the spring 
months of the year 2020, coinciding with the pan-
demic, an increase of severe lung pathologies in dogs 
was detected by veterinarians in Spain. Therefore, it 
is important to determine the infectious agent(s) and 
a potential role of SARS-CoV-2 infection. It is neces-
sary also to describe the pathological processes that 
could occur in those animals, which could be infected 
by SARS-CoV-2 and which show symptoms similar to 
humans affected by COVID-19. It is also highly rel-
evant to determine if dogs could become infected in a 
home environment where close human-pet interactions 
occur. Here, we describe the study of sick and healthy 
dogs regarding potential infection with SARS-CoV-2.
Materials and methods
Clinical study
A prospective study with forty dogs presenting pneu-
monia was performed between April and June 2020 in 
Spain. This study was conducted in several hospitals 
and clinics, in Madrid and Zaragoza (Spain). The inclu-
sion criteria were to present at least three of the fol-
lowing clinical signs: fever (rectal temperature higher 
than 39.5  °C), cough, fatigue, tachypnoea (higher than 
30 breaths per min), or crackles on lung auscultation. 
Gastrointestinal signs (vomiting and/or diarrhea) and 
tachycardia (higher than 130 beats per min) were also 
recorded. Dogs without evidence of pneumonia on 
imaging tests and dogs presenting signs that suggested 
cardiogenic oedema or tumors were excluded. The clin-
ical diagnosis of pneumonia was through various imag-
ing tests, including thoracic ultrasound. For a complete 
work-up dorsoventral and laterolateral thoracic radio-
graphs, abdominal ultrasound, and complete hema-
tologic work-up were performed on all dogs that had 
owner authorization. A clinical follow-up of all patients 
was performed and mortality was also recorded.
Twenty healthy dogs living with people with a SARS-
CoV-2-confirmed infection were included as animals 
exposed to the virus. These dogs did not present any 
symptoms at the time of sample taking, and therefore 
were considered healthy animals. The inclusion crite-
rion was the animals lived in homes where at least one 
person had been diagnosed with COVID-19. Exclusion 
criteria were pregnant females and dogs diagnosed with 
any ongoing pathology or infection.
The study was approved by the Ethical Committee 
of the Faculty of Health Sciences, Alfonso X el Sabio 
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University and all dog owners gave written informed 
consent.
Image analysis
Chest X-ray (CXR) was performed in two projections 
(Right Laterolateral (LL)/Dorsoventral (DV)). Thoracic 
radiographs and a study ultrasound were performed in 
sick dogs using a portable ultrasonographic device (My 
Lab Alpha Vet Esaote S.P.A, Barcelona, Spain) equipped 
with two multifrequency linear (3–13 MHz) and micro-
convex (8–12 MHz) transducer. The Vet BLUE protocol 
was used to study the lungs of each patient, the images 
were acquired at 4 acoustic windows on each side of the 
thorax at standardized anatomic sites (caudal, perihilar, 
middle and cranial), providing a total of 8 sites/patient. 
The pathological lung was recognized when the ultra-
sound lung rockets also called B lines were observed 
(Figure 1) or by the presence of other pulmonary ultra-
sound findings for consolidation (crushing, tissue, nod-
ule sign) (Figure 1).
Computed tomographic (CT) scans were obtained 
using 64-multidetector scanners (Aquilion, Toshiba) 
with all dogs positioned in sternal recumbency under 
general anaesthesia, the CT scan was performed dur-
ing temporary apnoea induced by hyperventilation. CT 
scans were examined by a radiologist. The general dis-
tribution of the lung lesions was classified as general-
ized, focal and uni or bilateral. The presence or absence 
of pleural effusion was studied with all techniques.
Immunoglobulins detection by immunoassays
Blood samples were collected in BD vacutainer plasma 
separator tubes (BD PST II, Becton Dickinson, Frank-
lin Lakes, NJ, USA), plasma was obtained and frozen 
at -20  °C until analysis. As a negative control, samples 
from dogs with no known virus exposure were used, 
kindly given by Centro de Transfusión Veterinario 
(Madrid, Spain).
To determine immunoglobulins (IgG) against 
SARS-CoV-2 in dog plasma samples, a highly sensi-
tive SARS-CoV-2 Spike S1 protein ELISA Kit was 
used (MyBioSource, San Diego, CA, USA) following 
the manufacturer’s instructions. Captured IgG against 
SARS-CoV-2 S1 protein were detected by goat anti-
dog IgG (H&L) polyclonal antibody conjugated with 
horse radish peroxidase (HRP) (Invitrogen, Carlsbad, 
CA, USA). Absorbance was measured at 450 nm using 
the Varioskan LUX, ver. 1.00.37 (Thermo Fisher Scien-
tific, Waltham, Massachusetts, USA). Results were cal-
culated using the SkanIt Software 5.0 for Microplate 
Readers RE, ver. 5.0.0.42 (Thermo Fisher Scientific). 
Values > 2.5OD of the negative control were considered 
as positives, with 2.14OD being the cutoff value to 
determine IgG against SARS-CoV-2.
To determine antibodies (IgM and IgG) against 
canine coronavirus that causes infections in enteric 
tract (CCoV), dog plasma samples were analyzed 
by two different commercial enzyme immunoassays 
(Eurovet veterinaria S.L., Daganzo de Arriba, Madrid, 
Spain) following the manufacturer’s instructions. Both 
immunoassays recognize two different strains of CCoV, 
CCoV type I (CCoV-I) and CCoV type II (CCoV-II). 
Absorbance was measured at 450  nm using the Vari-
oskan LUX, ver. 1.00.37 (Thermo Fisher Scientific). 
Results were calculated using the SkanIt Software 5.0 
for Microplate Readers RE, ver. 5.0.0.42 (Thermo Fisher 
Scientific). The S/P ratio was calculated as (ODsam-
ple—MVODNC)/(MVODPC—MVODNC), where MV 
Figure 1 Imaging with chest radiograph, sonographic images 
and CT of three different dogs. A Thoracic radiograph made in 
right lateral (left) and dorsoventral (right) showing a generalized 
severe interstitial opacity accentuated in the caudodorsal (arrows). B 
Sonographic images of two patients with severe dyspnea showing 
a diffused B line (left; arrow) and consolidation focal lesions (right; 
arrow). C Transverse (left) chest CT images showing bilateral focal 
peripheral ground‑glass opacities with intralobular and interlobular 
smooth septal thickening (arrow); sagittal (right) chest CT images 
showing diffuse opacities with consolidation and bronchial wall 
thickening (arrow).
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was mean value, NC was negative control and PC was 
positive control. When quantifying IgM, samples with 
the S/P ratio ≥ 0.250 were considered positives. When 
quantifying IgG, samples with the S/P ratio ≥ 0.240 
were considered positives.
To determine neutralizing antibodies (IgG) against 
canine adenovirus (CAV), canine parvovirus (CPV) and 
canine distemper virus (CDV), plasma samples were 
analyzed by an ELISA in solid phase (ImmunoComb 
Canine VacciCheck, Biogal Galed Laboratories Acs., 
Galed, Israel). The assays were performed following the 
manufacturer’s instructions. ImmunoComb images 
were digitalized and spot densities were quantified using 
Image Lab™ 5.0 Software (Bio-Rad, Hercules, CA, USA). 
Arbitrary units were calculated as follows: (sample spot 
intensity—sample mean background intensity)—(positive 
reference spot intensity—positive reference spot mean 
background intensity), and negative/positive criterion 
was applied following manufacturer’s instructions.
PCR analysis
Nasopharyngeal swabs (all dogs) and rectal swabs (sick 
dogs only) were collected and analyzed by Laboklin 
GmbH & Co. (Bad Kissingen, Germany) using conven-
tional PCR or real-time PCR (qPCR and RT-qPCR). 
Swabs were incubated in 750 µL MagNA Pure DNA Tis-
sue Lysis Buffer (Roche Diagnostics GmbH, DE-Man-
nheim, Germany) plus 75  µL Proteinase K (Carl Roth 
GmbH + Co. KG, DE-Karlsruhe, Germany) for 1  h at 
65  °C. Automated isolation of nucleic acids (RNA and 
DNA) was performed with the MagNA Pure 96 system 
from Roche Diagnostics GmbH according to manufac-
turer’s instructions. Nasopharyngeal swabs from sick 
dogs were tested for canine adenovirus type 2 (CAV-2) 
[16], Bordetella bronchiseptica [17], CDV [18], canine 
parainfluenza virus (CPIV) (in-house method), canine 
influenza A virus (CIV) [19] and canine herpesvirus-1 
(Canid alphaherpesvirus-1: CaHV-1) [20] by Taqman 
real-time PCR on a LightCycler®96 (Roche Diagnostics, 
Basel, Switzerland) and for Mycoplasma spp. [21] by con-
ventional PCR. Swabs from all sick dogs, and swabs from 
healthy dogs that presented α-SARS-CoV-2 IgG, were 
also tested for SARS-CoV-2 [22] by Taqman real-time 
PCR on a LightCycler®96 (Roche Diagnostics).
Histopathology
Lungs of two dogs (SER209 and SER222) were histologi-
cally evaluated after necropsy. The macroscopic exam 
evaluated congestion, oedema and the lung injury pat-
tern, evaluating whether there is scattered involvement 
by areas or if it is generalized throughout the lungs, as 
well as the presence and type of lesions. Lung samples 
were fixed in formalin 4% for 24  h, paraffin-embedded 
and 3 µm thick sections were obtained and stained with 
hematoxylin–eosin.
Statistical methods
Categorical variables were presented as percentages. For 
continuous variables, data distribution normality was 
evaluated with the Kolmogorov–Smirnov test. Continu-
ous data were presented as mean with standard deviation 
(SD) or median with interquartile range (IQR).
Results
Forty pathologic dogs met the inclusion criteria with the 
mean age of 8  years (range: 2  months to 13  years). Fif-
teen breeds were recorded with the most common being 
Cross-Breed 22.5% (9/40), Yorkshire terrier 12.5% (5/40), 
and German shepherd 10% (4/40). There were 22 females 
and 18 males.
The most common clinical signs were crackles on lung 
auscultation (100%), followed by cough (92.5%), tachyp-
noea (80%), fatigue (72.5%), tachycardia (60%), fever 
(57.5%), vomiting (37.5%) and diarrhoea (35%) (Table 1). 
The radiographic findings in the 40 analyzed dogs were 
consistent with mild to severe alveolar or interstitial pat-
tern, with pulmonary opacity accentuated in the caudo-
dorsal lung field. In 32.5% (13/40) of dogs a generalized 
increase in pulmonary opacity affecting all lung lobes 
was noted (Figure  1A). A focal alveolar infiltrate in the 
cranioventral lung field was detected in 50% (20/40) of 
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dogs. One or more pathological findings were observed 
during the ultrasound examination of the patients. 
The main sonographic features were dispersed B-line 
and rocket sign (100%; 31/31), partially diffused B-line 
(80.65%; 25/31) and pulmonary consolidations focal 
lesions (48.39%; 15/31). Complications such as pleural 
effusion were rarely seen (4%; 1/25) and pneumothorax 
was not detected (Figure 1B). The CT findings were pul-
monary parenchymal abnormalities (Figure 1C) and the 
lung lesions were bilateral in all evaluated dogs.
In order to assess the overall status of dogs, and consid-
ering that the number of white blood cells is frequently 
altered in an infection, we consider relevant to perform 
a hematologic evaluation on twenty-four pathologic 
patients. The count of white blood cells (WBC) was 
out of normal range in 58.3% of dogs with the number 
of neutrophils being abnormal in 75%, lymphocytes in 
37.5% and monocytes in 45.8% (Table 2).
Considering the altered immune cell numbers observed 
in peripheral blood and the clinical course, we proceeded 
to evaluate possible pulmonary pathogens. In order to 
determine whether the observed pathologies could be 
related to a SARS-CoV-2 infection or to other pathogens, 
PCR analysis was performed. All forty dogs were nega-
tive for SARS-CoV-2 (Table  3). Thirty-three dogs were 
additionally analyzed for a complete profile including the 
most common canine infectious agents. All of them were 
negative for CPIV, CIV, and CaHV-1. Mycoplasma spp. 
and CDV were detected as a single agent in 57.6% (19/33) 
and 3% (1/33), respectively (Table 3).
The pathologies in our patients were severe with 42.5% 
(17/40) dying of pneumonia during follow-up (Table 1), 
all from respiratory distress. The patients who survived 
had permanent radiographic changes in the lung paren-
chyma, with a predominance of the interstitial pattern, as 
well as reduced respiratory capacity. Two of the deceased 
dogs were necropsied in order to study lung tissue dam-
age. The macroscopic examinations showed congested, 
oedematous, and consolidated lung parenchyma with 
patchy involvement in both dogs. Both animals presented 
severe interstitial pneumonia with diffuse alveolar dam-
age. Furthermore, one dog (SER209) presented extensive 
congestion, haemorrhages (Figure 2A), and fibrin sheaths 
in the alveolar lumen with an inflammatory infiltrate of 
lymphocytes and macrophages (Figure  2B), with scat-
tered syncytia. Occasionally, alveoli are lined by Type 
II pneumocytes (Figure  2B). There was multifocal vas-
culitis with periarteriolar lymphocyte infiltrate and 
occasional vascular wall hyalinosis (Figure  2C). Animal 
SER222 showed intense autolytic changes with severe 
acute alveolar damage, vascular lesions such as conges-
tion, rich-protein alveolar oedema (Figure 2D), and hya-
line membranes that occluded alveolar lumina. Scant and 
disperse inflammatory cells, mainly macrophages with 
intracytoplasmic brown granular pigment (compatible 
with hemosiderin) were observed in alveolar septa. Inter-
estingly, some of these findings, particularly the scattered 
syncytia are usually present in some viral infections [23].
After testing for possible pathogens in the diagnosed 
dogs and analyzing the evaluated tissues, we set out to 
study the immune response against some of these infec-
tious agents in 17 dogs. Further, we also decided to study 
20 dogs that lived with people diagnosed with SARS-
CoV-2 infection, as a group of dogs potentially exposed 
to the virus, and which did not present symptoms at the 
time of sampling. First of all, information about vac-
cination was gathered to determine the immune status 
of dogs. Ten sick dogs had been vaccinated routinely 
according to recommendations by veterinarians but eight 
sick dogs did not receive any vaccine (Additional file 1). 
We have not detected any association between the vac-
cination patterns of pathological animals compared to 
healthy dogs.
Immunoglobulins G (IgG) against CAV, CPV and 
CDV were analyzed in peripheral blood samples from 
these sick and healthy dogs (Figure  3 and Additional 
file 2). Further, antibodies (IgM and IgG isotypes) against 
canine coronavirus that affects the enteric tract (CCoV), 
and also IgG against SARS-CoV-2 were studied for both 
groups (Figure  3 and Additional file  2). The number of 
dogs that presented IgG antibodies against SARS-CoV-2 
was higher in the group of healthy dogs in COVID-
19-positive households (25%; 5/20), compared to the 
pathological ones (5.88%; 1/17). Interestingly, the sick 
Table 2 Hematologic peripheral blood analysis
WBC White Blood Cells
a Median
b Interquartile range (IQR)
Hematologic Out of range parameters Normal  range Mean Standard deviation
N = 24 (%) (SD)
WBC (× 103cells/µL) 14 (58.3) 6.0–17.0 20.5 9.7
Neutrophils (× 103cells/µL) 18 (75) 3.0–11.5 16.7 9.1
Lymphocytes (× 103cells/µL) 9 (37.5) 1.0–4.8 1.9a 1.0–3.3b
Monocytes (× 103cells/µL) 11 (45.8) 0.2–1.4 1.2a 0.7–1.7b
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dog that presented antibodies against SARS-CoV-2 was 
negative for the detection of the virus in swabs studied 
by RT-qPCR, however Mycoplasma spp. and CDV were 
detected in this patient (Additional file  2 and Table  3). 
All five α-SARS-CoV-2 IgG-positive healthy dogs were 
negative to SARS-CoV-2 by RT-qPCR. All of them 
showed the same pattern of antibodies against some of 
the studied pathogens, with positives for α-CAV IgG, 
α-CPV IgG and α-CDV IgG (Additional file  2). Never-
theless, two of the five presented α-CCoV IgG while the 
Table 3 Infectious pathogens of sick dogs
CAV‑2: canine adenovirus type 2; CDV: canine distemper virus; CPIV: canine parainfluenza virus; CIV: canine influenza A virus; CaHV‑1: canine herpesvirus‑1; SARS‑
CoV‑2: severe acute respiratory syndrome coronavirus 2. Presence (+), absence (–), not determined (nd)
CAV-2 Mycoplasma spp. Bordetella 
bronchiseptica
CDV CPIV CIV CaHV-1 SARS-CoV-2
SER 01 −  +  + − − − − −
SER 02 −  + − − − − − −
SER 03 −  + − − − − − −
SER 04 nd nd nd nd nd nd nd −
SER 05 −  + − − − − − −
SER 06 nd nd nd nd nd nd nd −
SER 07 nd nd nd nd nd nd nd −
SER 08 nd nd nd nd nd nd nd −
SER 09 −  + − − − − − −
SER 10 −  + − − − − − −
SER 11 −  + − − − − − −
SER 12 −  + − − − − − −
SER 13 −  + − − − − − −
SER 14 −  + − − − − − −
SER 15 −  + −  + − − − −
SER 16 −  + − − − − − −
SER 17 −  + − − − − − −
SER 18 −  + −  + − − − −
SER 202 − – − − − − − −
SER 204 −  + − − − − − −
SER 205 −  + − − − − − −
SER 206 −  + − − − − − −
SER 207 −  + − − − − − −
SER 208 −  + − − − − − −
SER 209 −  + − − − − − −
SER 210 −  + − − − − − −
SER 211 − − − − − − − −
SER 212 − − − − − − − −
SER 213 − − − − − − − −
SER 214  +  + – – − − − −
SER 217 –  +  +  + − − − −
SER 220 –  + –  + − − − −
SER 222 –  + – – − − − −
SER 223 – – – – − − − −
SER 233 – – –  + – – – −
SER 234 –  + –  + – – – −
SER 235 – – – – – – – −
SER 301 nd nd nd nd nd nd nd −
SER 302 nd nd nd nd nd nd nd −
SER 303 nd nd nd nd nd nd nd −
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remaining three were not protected against canine coro-
navirus. Twelve healthy dogs presented α-CCoV IgG with 
two of these twelve being positive for α-SARS-CoV-2 
IgG (Figure  3 and Additional file  2). Seven pathological 
dogs presented α-CCoV IgG, but in this group all were 
negative for α-SARS-CoV-2 IgG (Figure 3 and Additional 
file 2).
Discussion
Dogs are currently considered to be less susceptible hosts 
for SARS-CoV-2 than cats or minks, despite the fact that 
several positive RT-qPCR test results in dogs have been 
reported [6]. Surveillance data from IDEXX laborato-
ries, show no positive results for SARS-CoV-2 in any of 
more than 1500 dog specimens submitted for respiratory 
PCR panels, suggesting that transmission from human 
to pet is very rare. However, veterinarians in Spain have 
observed an increase in aggressive lung pathologies in 
dogs during the human COVID-19 pandemic that have 
not responded to conventional antibiotic treatments. 
Moreover, the mortality rate due to respiratory disease is 
typically very low (1.2% and only 0.3% due to pneumonia) 
[24, 25]. Nevertheless, we found a mortality rate of 42.5% 
during follow-up. Dogs with very aggressive lung diseases 
showed a very similar appearance to humans presenting 
COVID-19 [26]. We cannot rule out the existence of an 
acute respiratory distress syndrome (ARDS) that gener-
ates the described pathological patterns. However, these 
cases in veterinary medicine are very uncommon and 
tend to have known etiology, usually a sequel to bacterial 
pneumonia, aspiration pneumonia, sepsis, or shock [27].
Historically, the most common pathogens associated 
with complex canine infectious respiratory disease have 
been CPIV, CAV-2, Bordetella bronchiseptica, Strepto-
coccus equi subsp. zooepidemicus, Mycoplasma cynos, 
CaHV-1, CDV, CIV, and CRCoV [25]. In our study, we 
detected eight of 33 analyzed dogs presenting classi-
cal primary respiratory pathogens, and we also detected 
IgM for CCoV in four dogs (3/17 pathological dogs and 
1/20 healthy dog). However, the presence of CRCoV 
is detected more frequently in dogs with mild clinical 
signs than in dogs with moderate or severe clinical signs 
[5]. Therefore, we can assume that it was not the agent 
responsible for the severe respiratory pathologies in these 
three dogs.
Interestingly, 26 of 33 analyzed dogs showed a posi-
tive test for Mycoplasma spp. Many Mycoplasma spp. 
are commensal organisms that colonize the mucous 
Figure 2 Histopathological study of lung tissues in sick dogs. Representative images of hematoxylin and eosin stained necropsy samples are 
shown. A Sample showing moderate vasculitis with rich‑protein alveolar oedema and haemorrhages. B Lung tissue showing alveolar lined by type 
II pneumocytes and inflammatory infiltrate in the alveolar lumens. C Arteriolar wall hyalinosis is shown. D Diffuse alveolar damage with oedema and 
intra‑alveolar hyaline membranes are shown. Scale bar: 200 µm (A, D) and 50 µm (B, C).
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membranes of the respiratory tract, and their role in 
canine infectious respiratory disease is not clear. More-
over, Mycoplasma cynos is the only species of the genus 
Mycoplasma significantly associated with pneumonia in 
dogs but it is still also unclear if M. cynos is a primary or 
secondary pathogen in dogs, because it can be cultured 
from the lungs of dogs, both with and without other 
identifiable infectious agents [28]. In a European study of 
dogs with canine infectious respiratory disease, seroprev-
alence of Mycoplasma spp. levels ranged from 20.7 to 
61.9% [29], but in another study with healthy dogs, myco-
plasma were isolated from 78 to 93% of throat swabs [25]. 
Moreover, mycoplasma infections are usually associated 
with other infections. It is interesting to note that myco-
plasma coinfections are very common in COVID-19 
human patients [30], and it also has been suggested that a 
coinfection or activation of latent mycoplasma infection 
in COVID-19 disease may be highly significant in deter-
mining a fatal disease course [31, 32].
Normally, the therapy response when treating canine 
respiratory tract diseases with drugs (antibiotics, bron-
chodilators, anti-inflammatories, antitussives, decon-
gestants, mucolytics, mucokinetics or expectorants) is 
adequate at alleviating the symptoms or reversing the 
disease. Nevertheless, our patients did not respond 
adequately to the therapeutic protocol. A major com-
mon pathogen has not been detected in our patients, so 
at the moment the causative agent of the pathologies is 
unknown. Further, the number of deaths was more than 
30 times higher than expected without clarified etiol-
ogy and curiously coincidental to a peak of the COVID-
19 pandemic in Spain. When analyzing deceased dogs, 
interstitial pneumonia that usually courses with nonspe-
cific lesions was detected. This manifestation has also 
been described in canine pathologies, such as canine 
Figure 3 Immune response of sick and healthy dogs. A Quantification of immunoglobulins (Ig) G against canine adenovirus (CAV), canine 
parvovirus (CPV) and canine distemper virus (CDV) in sick (red bars; n = 17) and healthy (blue bars; n = 20) dogs. Mean + standard error of the 
mean (SEM) are shown. Mann–Whitney U test; *p < 0.05. Scatter dot plots showing the quantification of IgM (B) and IgG (C) against canine 
coronavirus (CCoV) in sick and healthy dogs. Mean ± SEM (bars) and individual values (dots) are shown. Dotted line indicates the range of positives. 
D Quantification of IgG against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) in sick and healthy dogs. Mean ± SEM (bars) and 
individual values (dots) are shown. Dotted line indicates the range of positives. a.u.: arbitrary units.
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distemper, herbicide poisoning (paraquat) and systemic 
processes (principally, septicemia or uremia) [23]. How-
ever, it should be noted that the observed lesions are 
similar to those described for humans with COVID-19 
[2]. Especially, striking lesions observed in vessels, both 
lymphocytic vasculitis and the hyalinosis of the arteri-
olar wall [33]. However, all of them were negative for 
RT-qPCR tests for SARS-CoV-2 using nasopharyngeal 
and rectal samples. These results agree with a large-scale 
study that was recently carried out to assess SARS-CoV-2 
infection in 817 companion animals living in northern 
Italy, in which similarly none of the animals tested posi-
tive using RT-qPCR [11]. Likewise, it should be consid-
ered that viral particles have been detected in the skin 
endothelium of human patients despite the fact that they 
were negative when nasopharyngeal swabs were tested by 
RT-qPCR. Therefore, it would be useful to analyze SARS-
CoV-2 by immunohistochemistry and/or RT-qPCR in 
necropsy samples from our patients [34].
In a previous study on the presence of immunoglobu-
lins against SARS-CoV-2 in peripheral blood of pets, 487 
dogs were tested in China. They were serologically nega-
tive for anti-SARS-CoV-2 IgGs. Among them, sera from 
15 pet dogs and 99 feral dogs were collected from Wuhan 
City, but it should be noted that only one pet dog living 
with a confirmed human COVID-19 patient presented 
antibodies against SARS-CoV-2 [10]. However, in the 
Italian study, 3.4% of 188 dogs (and 3.9% of 63 cats) had 
measurable SARS-CoV-2 neutralizing antibody titers. 
None of these animals with neutralizing antibodies dis-
played respiratory symptoms at the time of sampling. As 
expected, dogs from SARS-CoV-2-positive households 
seemed to be significantly more likely to test IgG positive 
than those from SARS-CoV-2-negative households [11]. 
Finally, other researchers have determined that only half 
of the dogs artificially inoculated with SARS-CoV-2 sero-
converted [8].
Here we detected specific anti-SARS-CoV-2 canine 
immunoglobulins in one sick dog (1/17) and in 25% 
(5/20) of dogs living in COVID-19-positive households, 
indicating their susceptibility to SARS-CoV-2 infec-
tion. Seropositivity was significantly greater among pets 
from COVID-19-positive households compared to those 
with owners of unknown status. In the Italian study they 
found 12.8% (6/47) of dogs with anti-SARS-CoV-2 canine 
immunoglobulins in COVID-19-positive households, 
but only 1.5% (2/133) of dogs living in COVID-19-neg-
ative households. Of note, in our study the influence of 
the family environment was not evaluated in the group 
of sick dogs. Some owners presented COVID-19 symp-
toms, nevertheless they were not tested for SARS-CoV-2. 
Other owners had not presented symptoms during the 
pandemic. Therefore, it was decided to exclude this data 
due to a lack of reliable information.
Most people infected with SARS-CoV-2 display an 
antibody response between day 10 and day 21 after 
infection, and several studies have suggested that previ-
ous antibodies and T cells against endemic human cor-
onavirus may provide some degree of cross-protection 
from SARS-CoV-2 infection [35]. Further, there have 
been reports of pre-existing memory CD4 + T cells that 
are cross-reactive with SARS-CoV-2 and the common 
human cold coronaviruses HCoV-OC43, HCoV-229E, 
HCoV-NL63, or HCoV-HKU1 [36]. In our data, we did 
not find any correlation between α-CCoV and α-SARS-
CoV-2 IgG-positivity, although the low number of cases 
makes it difficult to reach a valid conclusion. Some 
viruses as CAV, CPV and CDV cause pathologies affect-
ing puppies with high mortality rates if they are not 
treated. Most routine protocols include the vaccination 
against these viruses, even before the pup is allowed to 
be in contact with other dogs. Since most of the dogs 
are vaccinated to this pathology we rule out any corre-
lation with anti-SARS-CoV-2 in our group of study.
In summary, we analyzed dogs affected by severe pul-
monary disease, all of which were negative for SARS-
CoV-2 by RT-qPCR. However, one sick dog (1/17) and 
five healthy dogs living in COVID-19-positive house-
holds (5/20) presented α-SARS-CoV-2 IgG. Our results 
suggest that even in the case of a canine infection it 
would be poorly transmissible. Moreover, dogs with own-
ers positive for SARS-CoV-2 could have been more likely 
to be exposed to infection during outbreaks.
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